Related Experiment Video
Updated: Jun 27, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Gaps in Guideline-Directed Medical Therapy for Heart Failure: A Cross-Sectional Study in an Underserved Population
Ayara O Ehinmisan1, Shilpi Jain-Aggarwal2, Shweta Karki3
1Cardiology, University Hospitals Cleveland Medical Center, Cleveland, USA.
Insights
Guideline-directed medical therapy (GDMT) for heart failure (HF) is under-prescribed in underserved populations. Targeted interventions are needed to address barriers and improve access to essential HF treatments.
Area of Science:
- Cardiology
- Public Health
- Health Disparities
Background:
- Heart failure (HF) presents a significant clinical and public health challenge globally.
- Guideline-directed medical therapy (GDMT) improves HF outcomes, yet significant gaps in its prescription and implementation persist.
- Understanding GDMT utilization patterns in diverse, underserved populations is crucial for optimizing disease management.
Purpose of the Study:
- To assess and evaluate the prescribing patterns of GDMTs.
- Focus on an underserved population within an urban federally qualified health center (FQHC).
Main Methods:
- Retrospective chart review of patients diagnosed with HF between May 2022 and June 2024.
- Classification of patients into HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) based on echocardiography.
- Comparison of baseline demographics and GDMT prescription rates between HFrEF and HFpEF groups.
Main Results:
- Fifty HF patients identified: 41 with HFrEF and 9 with HFpEF.
- Significant age difference: HFpEF mean age 68 years vs. HFrEF mean age 58 years (p=0.02).
- HFrEF GDMT prescription rates: Beta-blockers (BB) 93%, ACEi/ARB/ARNi 83%, MRA 29%, SGLT2 inhibitors 34%. HFpEF prescriptions were similar, except 0% received SGLT2 inhibitors (p=0.05 vs. HFrEF).
Conclusions:
- GDMT is under-prescribed in underserved populations, indicating a need for targeted interventions.
- Financial, systemic, and educational barriers contribute to these treatment gaps.
- Prioritizing patient education, financial counseling, provider training, and policy changes is essential to improve medication access and affordability for HF patients.
Background:
Heart failure (HF) remains a major clinical and public health challenge. Guideline-directed medical therapy (GDMT) has been shown to improve outcomes in patients with HF; however, gaps in the prescription and implementation of these therapies persist. These treatment gaps may contribute to suboptimal disease management and adverse clinical outcomes, highlighting the need to better understand patterns of GDMT utilization in diverse patient populations. In this study, we assessed and evaluated the prescribing patterns of GDMTs to an underserved population at an urban federally qualified health center (FQHC).
Methods:
We conducted a retrospective chart review of patients diagnosed with HF from May 2022 to June 2024 to assess the prescription of GDMT. Patients were classified based on echocardiographic findings as HF with reduced ejection fraction (HFrEF) (< 50%) and HF with preserved ejection fraction (HFpEF) (≥ 50%). Baseline demographics and prescription of GDMTs were compared between the two HF diagnoses.
Results:
Fifty patients with HF were identified in the study period, including 41 with HFrEF and nine with HFpEF. There was a significant difference in the mean age between patients diagnosed with HFpEF (68 years) as compared to patients with HFrEF (58 years) (p=0.02). Among patients with HFrEF, 93% (n=38) were prescribed beta-blockers (BB), 83% (n=34) were prescribed angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor-neprilysin inhibitors (ACEi/ARB/ARNi), 29% (n=12) were prescribed mineralocorticoid receptor antagonists (MRA), and 34% (n=14) were prescribed sodium-glucose cotransporter-2 inhibitors (SGLT2). Prescriptions for these medical therapies were similar among patients with HFpEF, except that 0% were prescribed an SGLT2 medication (p=0.05 for comparison with patients with HFrEF).
Conclusions:
GDMT is under-prescribed in underserved populations, underscoring the need for specific interventions to address financial, systemic, and educational barriers. Interventions such as patient education initiatives, financial counseling support, provider training programs, and policy changes to improve medication affordability and access should be prioritized to help close these treatment gaps.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy V: Interprofessional Care
Heart Failure I: Introduction
Heart Failure VII: Nursing Interventions
